UBS Initiates Coverage On Integra Lifesciences with Neutral Rating, Announces Price Target of $19
Integra LifeSciences Holdings Corporation
Integra LifeSciences Holdings Corporation IART | 0.00 |
UBS analyst Patrick Wood initiates coverage on Integra Lifesciences (NASDAQ:
IART) with a Neutral rating and announces Price Target of $19.
